Recommended COVID-19 vaccines for **people without immunocompromise, aged 6 months–4 years**, mRNA vaccines, *with vial icons and dosages*, May 2023*†

<table>
<thead>
<tr>
<th>Unvaccinated</th>
<th>Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COVID-19 vaccination status May 2023</strong></td>
<td></td>
</tr>
<tr>
<td>Previously received vaccine(s)</td>
<td></td>
</tr>
<tr>
<td><strong>Number of doses indicated, by manufacturer</strong></td>
<td></td>
</tr>
<tr>
<td>2 doses Moderna Bivalent 0.25 mL/25 ug <strong>OR</strong> 3 doses Pfizer-BioNTech Bivalent 0.2 mL/3 ug</td>
<td>1 dose monovalent Moderna</td>
</tr>
<tr>
<td>1 dose Moderna Bivalent 0.25 mL/25 ug</td>
<td>2 doses monovalent Moderna</td>
</tr>
<tr>
<td>1 dose Moderna Bivalent 0.2 mL/10 ug</td>
<td>2 doses monovalent Moderna and 1 dose bivalent Moderna</td>
</tr>
<tr>
<td>2 doses Pfizer-BioNTech Bivalent 0.2 mL/3 ug</td>
<td>1 dose monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td>1 dose Pfizer-BioNTech Bivalent 0.2 mL/3 ug</td>
<td>2 doses monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td>2 doses Pfizer-BioNTech Bivalent 0.2 mL/3 ug</td>
<td>3 doses monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td><strong>VACCINATION COMPLETE</strong></td>
<td></td>
</tr>
</tbody>
</table>

*For administration intervals, see Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

†Children who receive the Pfizer-BioNTech COVID-19 Vaccine and transition from age 4 years to 5 years during the 3-dose vaccination series must complete the series they start (i.e., receive the 0.2 mL/3 ug dosage supplied in vials with a maroon cap and label with a maroon border for all 3 doses).

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech
Recommended COVID-19 vaccines for people without immunocompromise, aged 5 years, mRNA vaccines, with vial icons and dosages, May 2023*†

*For administration intervals, see Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.
†Children who receive the Pfizer-BioNTech COVID-19 Vaccine and transition from age 4 years to 5 years during the 3-dose vaccination series must complete the series they start (i.e., receive the 0.2 mL/3 ug dosage supplied in vials with a maroon cap and label with a maroon border for all 3 doses).
Children who transition from age 5 years to 6 years during the Moderna vaccination series should receive 2 doses of Moderna COVID-19 Vaccine (0.25 mL/25 ug; dark blue cap and label with a gray border).

Key
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech
Recommended COVID-19 vaccines for **people without immunocompromise, aged 6–11 years**, mRNA vaccines, with vial icons and dosages, May 2023*†

*For administration intervals, see Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.
†Children who transition from age 5 years to 6 years during the Moderna vaccination series should receive 2 doses of Moderna COVID-19 Vaccine (0.25 mL/25 ug; dark blue cap and label with a gray border).

**Key**
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech
Recommended COVID-19 vaccines for **people without immunocompromise, aged 12 years and older**, mRNA vaccines, *with vial icons and dosages, May 2023*†

---

**COVID-19 vaccination status May 2023**

<table>
<thead>
<tr>
<th>Unvaccinated</th>
<th>Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously received vaccine(s)</td>
<td></td>
</tr>
<tr>
<td>Number of doses indicated, by manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

---

**VACCINATION COMPLETE†**

*For administration intervals, see Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.
†People ages 65 years and older have the option to receive 1 additional bivalent mRNA dose at least 4 months after the first dose of a bivalent mRNA vaccine; see Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech
**Recommended COVID-19 vaccines for people without immunocompromise, aged 6 months–4 years, mRNA vaccines, May 2023**

**COVID-19 vaccination status May 2023**

<table>
<thead>
<tr>
<th>Previously received vaccine(s)</th>
<th>Unvaccinated</th>
<th>Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 dose monovalent Moderna</td>
<td>2 doses monovalent Moderna and 1 dose bivalent Moderna</td>
<td>1 dose monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td>2 doses monovalent Moderna</td>
<td>2 doses monovalent Moderna</td>
<td>2 doses monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td>1 dose bivalent Moderna</td>
<td>1 dose bivalent Moderna</td>
<td>3 doses monovalent Pfizer-BioNTech</td>
</tr>
<tr>
<td>2 doses bivalent Moderna OR 3 doses bivalent Pfizer-BioNTech</td>
<td>2 doses bivalent Pfizer-BioNTech</td>
<td>2 doses bivalent Pfizer-BioNTech</td>
</tr>
<tr>
<td>1 dose bivalent Pfizer-BioNTech</td>
<td>1 dose bivalent Pfizer-BioNTech</td>
<td></td>
</tr>
</tbody>
</table>

**VACCINATION COMPLETE**

*For product- and vaccination history-specific dosages and administration intervals, see Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.*

**Key**
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech
Recommended COVID-19 vaccines for **people without immunocompromise, aged 5 years**, mRNA vaccines, May 2023*

*For product- and vaccination history-specific dosages and administration intervals, see Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

---

---
Recommended COVID-19 vaccines for **people without immunocompromise, aged 6 years and older**, mRNA vaccines, May 2023*

*For product-specific dosages and administration intervals, see Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

†People ages 65 years and older have the option to receive 1 additional bivalent mRNA dose at least 4 months after the first dose of a bivalent mRNA vaccine; see Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech